These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10552989)

  • 21. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
    Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S
    Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
    Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
    Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
    Espinel-Ingroff A; Canton E; Gibbs D; Wang A
    J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
    Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
    Messer SA; Kirby JT; Sader HS; Fritsche TR; Jones RN
    J Antimicrob Chemother; 2004 Dec; 54(6):1051-6. PubMed ID: 15564286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
    Moris DV; Melhem MSC; Martins MA; Souza LR; Kacew S; Szeszs MW; Carvalho LR; Pimenta-Rodrigues MV; Berghs HAM; Mendes RP
    J Med Microbiol; 2012 Dec; 61(Pt 12):1758-1765. PubMed ID: 22956748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
    Ruhnke M; Schmidt-Westhausen A; Trautmann M
    Antimicrob Agents Chemother; 1997 Mar; 41(3):575-7. PubMed ID: 9055995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
    Martín-Mazuelos E; Gutiérrez MJ; Aller AI; Bernal S; Martínez MA; Montero O; Quindós G
    J Antimicrob Chemother; 1999 Apr; 43(4):477-81. PubMed ID: 10350375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
    Krishnarao TV; Galgiani JN
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
    Chryssanthou E; Cuenca-Estrella M
    J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal susceptibility of 95 yeast strains isolated from oral mycoses in HIV-negative and HIV-positive patients.
    Mareş M; Mareş M; Rusu M
    Bacteriol Virusol Parazitol Epidemiol; 2008; 53(1):41-2. PubMed ID: 19241996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.